THE EFFECTS OF STATIN THERAPY ON PNEUMONIA OUTCOMES
Abstract
HMG-CoA reductase inhibitors (statins) are the most prescribed class of drugs in the world. Some authors suggest that positive effects of statins were reported for statins against pneumonia. These positive studies data were counterbalanced by at least one negative prospective cohort study. Where lies the truth? Better understanding the statins influence and their potential role in pathophysiological pneumonia mechanisms is needed because of high quantity of subjects receiving statins with numerous medical conditions significantly associated with increased short-term mortality.Downloads
References
Chatzizisis Y.S. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. / Y.S. Chatzizisis, K.C. Koskinas, G. Misirli [et al] // Drug Saf. – 2010. – № 33. – Р. 171–187.
De Loecker I. Statins in the critically ill / Isabelle De Loecker // Annals of Intensive Care. – 2012 – № 2:1. – P. 1–12.
Terblanche M. Statins and sepsis: multiple modification at multiple levels. / M. Terblanche, Y. Almog, R. Rosenson [et al] // Lancet Infect Dis. – 2007. – № 7. – P. 358–368.
Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. / R. Kones // Drug Des Devel Ther. – 2010. – № 9. – P. 383–413.
Kostapanos M.S. An overview of the extra-lipid effects of rosuvastatin. / M.S. Kosta panos, H.J. Milionis, M.S. Elisaf // J Cardiovasc Pharmacol Ther. – 2008. – № 13. – P. 157–174.
Weitz-Schmidt G. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. / G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann, [et al] // Nature Med. – 2001. – № 7. – P.687–692.
Endo A. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. / A. Endo, M. Kuroda & Y. Tsujita // J. Antibiot. (Tokyo) – 1976. – № 29. – P. 1346–1348.
Endo A. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. / A. Endo, Y. Tsujita, M. Kuroda, K. Tanzawa // Eur. J. Biochem. – 1977. – № 77. – P. 31–36.
Tobert J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. / J.A. Tobert. // Nature Reviews Drug Discovery. – 2003. – № 2. - P. 517–526.
Corsini A. New insights into the pharmacodynamic and pharmacokinetic properties of statins. / A. Corsini, S. Bellosta, R. Baetta [et al.] // Pharmacol Ther. – 1999. – № 84. – P.413–28.
Howe D. Coxiella burnetii inhabits a cholesterol-rich vacuole and influences cellular cholesterol metabolism. / D. Howe, R.A. Heinzen // Cell Microbiol. – 2006. – № 8. – P.496–507.
Bjorkhem-Bergman L. Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. / L. Bjorkhem-Bergman, P. Bergman, J. Andersson, J.D. Lindh // PLoS ONE. – 2010. - doi: e10702. doi:10.1371/journal.pone.0010702.
Bergman P. Studies on the Antibacterial Effects of Statins - In Vitro and In Vivo / P. Bergman, C. Linde, K. Pütsep, A. Pohanka [et all.] // PLoS ONE. – 2011. – doi:10.1371/journal.pone.0024394
Jain M.K. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. / M.K. Jain, P.M. Ridker // Nat Rev Drug Discov. – 2005. – № 4. – P. 977–987.
Horn M.P. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. / M.P. Horn, S.M. Knecht, F.L. Rushing, J. Birdsong, C.P. Siddall [et al.] // J Pharmacol Exp Ther. – 2008. – № 326. – P. 135–143.
Chaudhry M.Z. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. / M.Z. Chaudhry, J.H. Wang, S. Blankson, H.P. Redmond // Surg Infect (Larchmt). – 2008. – № 9. – P. 183–194.
Jerwood S. Unexpected antimicrobial effect of statins. / S. Jerwood, J. Cohen // J Antimicrob Chemother. – 2008. – № 61. – P. 362–364.
Welsh A.M. Antimicrobial action of atorvastatin and rosuvastatin. / A.M. Welsh, P. Kruger, J. Faoagali // Pathology. – 2009. – № 41. – P. 689–691.
Rosch J.W. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J.W. Rosch, A.R. Boyd, E. Hinojosa, T. Pestina, Y. Hu [et al.] // J Clin Invest. – 2010. – № 120. – P. 627–635.
Chow O.A. Statins enhance formation of phagocyte extracellular traps. / O.A. Chow, M. von Kockritz-Blickwede, A.T. Bright, M.E. Hensler, A.S. Zinkernagel [et al.] // Cell Host Microbe. – 2010. – № 8. – P. 445–454.
Bjorkhem-Bergman L. What is a relevant statin concentration in cell-experiments claiming pleiotropic effects? / L. Bjorkhem-Bergman, J.D. Lindh, P. Bergman // J Clin Pharmacol. – 2011. – Vol. 72, Is. 1. – P. 164–165.
Bielinska A. Statins–are they potentially useful in rheumatology? / A. Bielinska, P. Gluszko // Pol Arch Med Wewn. – 2007. – № 117. – P. 420–425.
Welsh A.M. Antimicrobial action of atorvastatin and rosuvastatin. / A.M. Welsh, P. Kruger, J. Faoagali // Pathology. – 2009. – № 41. – P. 689–691.
Masadeh M. Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin / M. Masadeh, N. Mhaidat, K. Alzoubi, S. Al-azzam, Z.Alnasser // Annals of Clinical Microbiology and Antimicrobials. – 2012. – № 11 (13). – P. 1–5.
Tleyjeh I.M. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. / I.M. Tleyjeh, T. Kashour, F.A. Hakim [et al] // Arch Intern Med. – 2009. - № 169. – P. 1658-1667.
Kozarov E. View of statins as antimicrobials in cardiovascular risk modification / E. Kozarov, T. Padro, L. Badimon // Cardiovasc Res. – 2014. – № 102 (3). – P. 362–374.
Viasus D. Statins for community-acquired pneumonia: current state of the science. / D. Viasus, C. Garcia-Vidal, F. Gudiol, J. Carratala // Eur J Clin Microbiol Infect Dis. – 2010. – № 29. – P. 143–152.
Novack V. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. / V. Novack, M. Eisinger, A. Frenkel [et al] // Intensive Care Med. – 2009. – № 35. – P. 1255–1260.
Viasus D. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial / D. Viasus, C. Garcia-Vidal, A.F. Simonetti [et al] // BMJ Open. – 2015. – L–1328 abstract.
Terblanche M. Statins and sepsis: multiple modifications at multiple levels. / M. Terblanche, Y. Almog, R.S. Rosenson [et al] // Lancet Infect Dis. – 2007. – № 7. – P. 358–368.
Polgreen L.A. Increased statin prescribing does not lower pneumonia risk / L.A. Polgreen, E.A. Cook, J.M. Brooks [et al] // Clin Infect Dis. – 2015. – doi:10.1093/cid/civ190.
Feldman C. Prior Statin Use Is Associated With Improved Outcomes in Community-Acquired Pneumonia. / C. Feldman, E. Shaddock // Am J Med. – 2008. – № 121 (11). – P. 1002–1007.
Patel J. M. Pre-emptive or early adjuvant simvastatin therapy in elderly patients with infection and sepsis / J. M. Patel, H. Greenwood, G. Walton [et al] // Lancet. – 2014. – Poster 51. – P. 76.
Mortensen E.M. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia / E.M. Mortensen, M.J. Pugh, L.A. Copeland [et al] // Eur Respir J. – 2008. – № 31. – P. 611–617.
Christensen S. Preadmission statin use and one-year mortality among patients in intensive care - A cohort study / S. Christensen, R. W. Thomsen, M. B. Johansen [et al] / Critical Care. – 2010. – № 14. – P. 645–650.
Schmidt H. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. / H. Schmidt, R. Hennen, A. Keller [et al] // Intensive Care Med. – 2006. – № 32. – P. 1248–1251.
Dichtl W. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. / W. Dichtl, J. Dulak, M. Frick [et al] // Arterioscler Thromb Vasc Biol. – 2003. – № 23. – P. 58–63.
Diomede L. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. / L. Diomede, D. Albani, M. Sottocorno [et al] // Arterioscler Thromb Vasc Biol. – 2001. – № 21. – P. 1327–1332.
Pruefer D. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. / D. Pruefer, J. Makowski, M. Schnell [et al] // Circulation. – 2002. – № 106. – P.2104–2110.
Steiner S. Simvastatin blunts endotoxin-induced tissue factor in vivo. / S. Steiner, W.S. Speidl, J. Pleiner [et al] // Circulation. – 2005. – № 111. – P.1841–1846.
Doggen C.J. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. / C.J. Doggen, R.N. Lemaitre, N.L. Smith [et al] // J Thromb Haemost. – 2004. – № 2. – P. 700–701.
Hothersall E . Potential therapeutic role for statins in respiratory disease / E .Hothersall, C. McSharry, N. C. Thomson. // Lancet. – 2010. – № 367. – P. 1095–1099.
Stoll G. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. / G. Stoll, M. Bendszus // Stroke. – 2006. – № 37. – P. 1923–1932.
Smeeth L. Risk of myocardial infarction and stroke after acute infection or vaccination. / L. Smeeth, S.L. Thomas, A.J. Hall [et al] // N Engl J Med. – 2004. – № 351. – P. 2611–2618.
Smeeth L. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. / L. Smeeth, C. Cook, S. Thomas [et al] // Lancet. – 2006. – № 367. – P. 1075–1079.
Cheng H.H. Beneficial effects of statins on outcomes in pneumonia: a systematic review and meta-analysis. / H.H. Cheng, T.T. Tang, Q. He [et al] // Eur Rev Med Pharmacol Sci. – 2014. – № 18(16). – P. 2294–305.
Shankar-Hari M. The Influence of Statin Exposure on Inflammatory Markers in Patients With Early Bacterial Infection. Pilot Prospective Cohort Study/ M. Shankar-Hari, A. Donnelly, R. Pinto// BMC Anesthesiol. – 2014; – № 14 (106). – P. 1023–1025.
Yende S. Understanding the Potential Role of Statins in Pneumonia and Sepsis / S. Yende, E. B. Milbrandt, J. A. Kellum [et al] // Crit Care Med. – 2011. – № 39 (8). – P. 1871–1878.
Waknine Y. Statin Fails in ICU Pneumonia Trial / Y. Waknine/ JAMA. Published online 2013.
Majumdar S.R. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. / S.R. Majumdar, F.A. McAlister, D.T. Eurich [et al] // BMJ. – 2006. – № 333. – P. 999.
Fernandez R. Statin therapy prior to ICU admission: protection against infection or a severity marker? / R. Fernandez, V.J. De Pedro, A. Artigas // Intensive Care Med. – 2006. - № 32. – P.160–164.
Chalmers J. D. Statins in community acquired pneumonia: Evidence from experimental and clinical studies. / J.D. Chalmers, P. M. Short, P. Mandal, A. R. Akram. // Intensive Care Med. – 2010. – Vol. 104, Iss. 8. – P. 1081–1091.
Liao J.K. Pleiotropic effects of statins. / J.K. Liao, U. Laufs // Annu Rev Pharmacol Toxicol. – 2005. – № 45. – P. 89–118.
Undas A. Statins and blood coagulation. / A. Undas, K.E. Brummel-Ziedins, K.G. Mann // Arterioscler Thromb Vasc Biol. – 2005. – № 25. – P. 287–294.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
